chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shortly after my second vaccine, I had a normal reaction, I had body aches, headache, and all of it was gone in 24 hours. September 11, my left eye swelled. It was like a semi-circle inside of my left eye and extended to above and below. September 12, my other eye (right) did the same thing. My other eye was still swollen but it had started to come down. On the 13th, My lips swelled. My eye swelling was starting to fade that day. I started having migrating hives randomly around my body. They were tolerable, but I didn't like it. Those would continue through two weeks. I got my Moderna Booster on the October 7th; I was still having the hives randomly. I think they gave me a full dose of the booster. I had sore arm, body aches and headaches for 24 hours, too. My hives continued to appear randomly on my body through the time when on October 21st, I had two vaccines: flu shot, and second shingles shot. On the 23rd, ever since then, I've been pretty awful. The hives turned into huge welts, like dinner plate sized welts that I would get anywhere on my body. They were painful. On October 15th, she gave me treatment, Pepcid twice a day; Xyzal 3 times a day; Singulair once a day; Benadryl once a day. On October 23rd, I received a steroid injection at urgent care or after hours that is on the weekend and been on prednisone. I got on prednisone on the 30th after the steroid injection wore off and the hives/welts came back with a vengeance, and they put me on prednisone. I was on that for 10 days. That calmed it down greatly. I am still taking all the meds that she originally told me to take but the symptoms are much better. Today I have three hives. I am doing so much better. I am 95% better but still on meds. I have an appt with my doctor next week for follow up.
About 10 days after the shot, my arm started itching. It itched from the elbow to the shoulder for about four days and then I?ve got a red circular rash that I googled and found listed as ?Covid arm?
Patient is a 81 y.o. male patient pmh adenocarcinoma of the lung, copd, pafib, htn who presents to ED with cough and abdominal pain.   Pneumonia of right lower lobe 2/2 COVID, Acute exacerbation of copd, acute pulmonary embolism without acute cor pulmonale- not seen on previous  Hemoptysis, persistent  COVID + on resp panel  Lactic acidosis on admission, resolved  CT chest showed small nonobstructive left lower lobe pulmonary embolism. No central emboli or cardiac strain. No PE found on repeat CT of chest.  Urine antigens and  MRSA probe negative BC x2 NGTD TTE LV segmental wall motion normal, EF- 62% Continue breathing treatments, duonebs scheduled, dulera. Acapella valve to assist with sputum production  Completed course of steroids  Day 8 of cefepime Multiple CXR show patchy right midlung infiltrate.  Continue O2 as increased work of breathing, wean as tolerated  Adjusted dose of xarelto after speaking with hematology on 10/6, lower dose to afib dosing instead of load for PE as CT showed no evidence of PE on repeat. However, after discussion with pulm on 10/8, will hold xarelto given persistent hemoptysis. Per pulm, hold AC until patient is seen by heme onc in clinic.    Lung adenocarcinoma He appears to be receiving radiation and tagrisso 80 daily is listed as a home med Held inpatient, will follow up outpatient  Will continue to hold until patient is seen in OP heme onc   Paroxysmal atrial fib Lopressor for rate control  Stop xarelto d/t continued hemoptysis    Essential htn Hold home meds at this time with borderline Bps  Diarrhea- resolved  Check Cdiff for completeness, negative 10/5   Cachexia Bmi 20
Diarrhea, mild temperature, sore body initially. 3 days after pain in right leg. It feels like a sharp stabbing pain. Like a charley horse or dehydration. Drank water and Gatorade does not stop pain. Started to take 81 mg aspirin and did not stop pain. Just went to Dr. for blood test on 4/14/21.
Initial report received from a healthcare professional on 30 April 2013.  A 28-year-old female patient had received an intramuscular first dose of ADACEL vaccine (lot number: U4612AA, anatomical site of vaccination was not reported) on 30 April 2013. The patient was pregnant at the time of vaccination. The patient's last menstrual period date was 03 September 2012 and estimated delivery date was reported as 10 June 2013. The patient's health during pregnancy, medical history, risk factors and concomitant medications were not reported. As of 30 April 2013, the patient had not experienced any adverse events. Documents held by sender: none.
Information was received on 14-MAR-2017 from a health care worker concerning an unknown number of unspecified patients. No medical history, concomitant medications or patient demographics were reported. The unspecified patients were each administered improperly stored vaccines on unknown dates, starting after 01-JUN-2015. There were several different sets of excursion conditions with different vaccines involved. The nurse confirmed that while many of the vaccines lots are now expired, all improperly stored doses were not expired at the time of administration. No adverse effects were reported. The lots of GARDASIL involved in the temperature excursions were lot J009788, expired 17-MAR-2016, K003520, expired 20-NOV-2016 and lot K006960, expired 19-FEB-2017. Other vaccines involved in the temperature excursion were PNEUMOVAX23 (MARRS# 1703USA014563), RECOMBIVAX HB (MARRS# 1703USA014564),  GARDASIL9 (MARRS #1703USA014565), PEDVAX HIB (MARRS#1703USA014567) and VARIVAX (MARRS# 1703USA014566). Follow-up information was received on 20-MAR-2017 from the reporter. She reported that GARDASIL doses were administered 22 times; 02-JUL-2015, 13-JUN-2015, 14-JUL-2015, 15-JUL-2015, 11-AUG-2015, 12-AUG-2015, 14-SEP-2015, 15-SEP-2015, 15-SEP-2015, 16-SEP-2015, 13-NOV-2015, 29-DEC-2015, 23-FEB-2016, 19-APR-2016, 26-APR-2016, 06-MAY-2016, 03-JUN-2016, 09-AUG-2016, 23-AUG-2016, 28-AUG-2016, 16-SEP-2016 and 13-JAN-2017 for lot K006960 (out of range 308 hours, 30 minutes) and dose administered on 28-SEP-2015, 15-OCT-2015 and 27-OCT-2015 for lot K003520. Temperature was out of range 303 hours, 30 minutes. No information was provided for lot J009788. No patient identifiers were provided. Additional information has been requested.  This is one of several reports by the same reporter.
Information has been received from a consumer concerning her 8 year old grandson with no medical history who in 2001 was vaccinated with a 0.5 ml first dose of MMR II, intramuscularly. There was no concomitant medication. In 2001 after the patient received the MMR II the patient developed autism. According with the reporter "it was like a light switch", he stopped jabbering and eating. He would only drink juice from a green sippy cup. He has improved over the last year while following a strict organic diet. The patient sought unspecified medical attention. Upon internal review autism was determined to be an other important medical event. Additional information has been requested.
This is a verbatim narrative as reported on the internet, accessed on 28 July 2011. According to the web site these reported were from FDA VAERS. "FLUMIST problem was reported on Nov 27, 2007. Female patient, 13 years of age, was vaccinated with FLUMIST on Nov 16, 2007. "Rec'd vaccine on 11/13/07. On 11/14/07 began with (L) upper arm tenderness. On 11/15/07 seen in office, significant tenderness with about 2 1/2" area of erythema/warmth, painful to move arm - treated with KEFLEX with improvement." None. N/A. Patient recovered."
3 days later I started having sever shooting and stabbing pain on the entire left side of my face that would not go away. The pain started in my teeth, jaw, temple, eye and ear. The next day I went to the dentist thinking it was my wisdom teeth, they checked my teeth, did ex rays and checked for infection but found nothing. Went to my primary care flight doc and she was un sure what was going on. Then I went to the Emergency room and I was diagnosed with Trigeminal Neuralgia of the face.
10/4/21- woke up with chest hurting.  chills. whole body hurt including joints.  He took blood oxygen and it was low 70's.  Dizzy when standing.  Considered going to hospital but didn't.  Next morning he was fine again.
Diarrhea, Chills, Fever, Sweating, Headache, Burning sensation on top of hands.
indication=Treatment of COVID-19; indication=Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 23Feb2021 as dose 1, single (Lot number: EL9267), on 16Mar2021 as dose 2, single (Lot number: EN6206) and on 06Oct2021 as dose 3 (booster), single (Lot number: EW016) at the age of 44 years for covid-19 immunization. The patient's relevant medical history included: "asthma" (unspecified if ongoing); "Allergies" (unspecified if ongoing). Concomitant medication(s) included: ASPRIN, start date: 03May2022; DOXYCYCLINE MONOHYDRATE, start date: 17May2022; DEXAMETHASONE, start date: 13May2022, stop date: 22May2022; SAXENDA, start date: Jul2020; IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE SOLUTION, start date: 13May2022; ALBUTEROL SULFATE, start date: 05May2022, stop date: 13May2022; BUDESONIDE, start date: 13May2022; BUDESONIDE, start date: Apr2020; ALPRAZOLAM, start date: May2018; MELOXICAM, start date: 09Mar2022, stop date: 03May2022; METRONIDAZOLE, start date: 22Feb2022; AZELASTINE, start date: 25Mar2022; EXHANCE, start date: 05Jan2022; TURMERIC +, start date: Mar2021; ELDERBERRY [SAMBUCUS NIGRA], start date: Mar2020; GLUCOSAMINE CHONDROITIN [CHONDROITIN SULFATE;GLUCOSAMINE], start date: Mar2020; MONTELUKAST, start date: May2018; MULTIVITAMIN [VITAMINS NOS], start date: May2017; also reported as other medication in 2weeks. Past drug history included: Known allergies: sulphur drugs, reaction(s): "Drug Allergy". The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "indication=Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, suspected covid-19 included Paxlovid (Lot number: FX4468) from 04May2022 to 09May2022. Clinical course was reported as, Several days completing the Paxlovid series, On 13May2022 at 05:00, covid symptoms shortness of breath, difficulty breathing, wheezing, congestion returned and were worse then before starting treatment. Treatment received for symptoms included breathing treatments and oral steroids. Patient was recovering from symptoms.
17MAY91 sore throat, fever off & on, lethargic; persists through today 21MAY91; 3MAY91 soreness & redness @ both sites; Taken children's aspirin for sx;
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 44-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Lupus" (unspecified if ongoing), notes: Lupus; "asthma" (unspecified if ongoing); "known allergies Latex" (unspecified if ongoing), notes: known allergies Latex. Concomitant medication(s) included: PLAQUENIL [HYDROXYCHLOROQUINE PHOSPHATE]; ZOLOFT; MINOCYCLINE. Past drug history included: Morphine, reaction(s): "known allergies morphine", notes: known allergies morphine. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID-19". Adverse event start date was 01Jun2022. Right arm and leg tremors days 1-5 and then today 09Jun (day 10 from first dose of antivirals) I am sick again and testing positive. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (09Jun2022) positive, notes: testing positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Antiviral Paxlovid was given as treatment for covid-19, start date 31May2022 and stop date 05Jun2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
fainting spells or passing out; severe stomach pain, abdominal pain; nausea; Swollen lymph nodes in three places like a triangle; low blood pressure with faint pulse; faint heart beat or rate with flutters; lightheadedness; blurry vision; right ear ache; face flush or red face; burning sensation on his hands; red rash on under arm; HEART FLUTTER; A spontaneous report was received from a Consumer concerning himself as a 72 Years-old male elder patient who  experienced severe stomach pain, nausea, abdominal pain, swollen lymph node in three places like a triangle, low blood pressure with a faint pulse, faint heartbeat or rate with flutters, dizziness, lightheadedness, fainting spells or passing out, blurry vision, right earaches, facial flushness or red face, burning sensation on his hand and red rash on his under arm.  The patient's medical history was low glycemia and atrial arrhythmia.His concomitant medications were reported as Vitamin D31000 IU as supplement, Prevacid 30 for acid reflux prevention  and Magnesium 400mg as supplement.  On 15 Feb 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: 007M20A) for prophylaxis of COVID-19 infection.  On an unspecified date, the patient experienced fainting spells which is medically significant and the other events are severe stomach pain, nausea, abdominal pain, swollen lymph node in three places like a triangle, low blood pressure with a faint pulse, faint heartbeat or rate with flutters, dizziness, lightheadedness, blurry vision, right earaches, facial flushness or red face, burning sensation on his hand and red rash on his under arm.   No treatment information was provided.   Action taken with mRNA-1273 in response to the events was Unknown.   The outcome of the event(s) severe stomach pain, nausea, abdominal pain, swollen lymph node in three places like a triangle, low blood pressure with a faint pulse, faint heartbeat or rate with flutters, dizziness, lightheadedness, fainting spells or passing out, blurry vision, right earaches, facial flushness or red face, burning sensation on his hand, red rash on his under arm were  Unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
passed out; doesn't remember much; fatigue; incontinence; tingling of toes; shaking; extreme weakness; unable to lift arms, legs or move. Could not turn over; achy; chills; 39 days between 1st and 2nd dose; A spontaneous report was received from a consumer concerning a 37 Years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced achy, chills, shaking, passed out, incontinence, extreme weakness, tingling toes, fatigue and 39 days between 1st and 2nd dose.   The patient's current medical history included several autoimmune disorders, Rheumatoid arthritis, Raynaud's, Ankylosing spondylitis. Patient has had bladder surgery and reports having difficulty with urinary incontinence No relevant concomitant medications were reported.    On 01 March 2021, prior to the onset of the events, the patient received the second of two planned doses of mRNA-1273 (lot/batch:006m20a) unknown route and in left arm for prophylaxis of COVID-19 infection. On 01 March 2021, the patient experienced 39 days between 1st and 2nd dose, and at the same night after the vaccination the patient began to felt achy, chills.  On 02 March 2021, the patient experienced the events shaking, passed out, incontinent, extreme weakness, unable to lift her arms, legs and could not move or turn over, tingling in her toes. Ambulance took patient to hospital meanwhile patient was in and out of consciousness. She came back to home and experienced weakness and fatigue. The event Passed out was a serious event.   Laboratory details not included. Treatment details included as IV fluids was given in the hospital. Action taken with mRNA-1273 in response to the events was not applicable. On 01 March 2021, the outcome of the event 39 days between 1st and 2nd dose was Resolved.; Reporter's Comments: This report refers to a case of inappropriate schedule of vaccine for mRNA-1273, lot # 006M20A with associated AEs achy, chills, shaking, incontinence, extreme weakness, fatigue, loss of consciousness. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Information has been received from a licensed practical nurse concerning a 16 year old female with a history of an spleen enlarged and a penicillin allergy who on 05-FEB-2008 was vaccinated intramuscularly with Gardasil (Lot # 659962/1740U).  There was no concomitant medication.  On 03-MAR-2008 the patient began experiencing body aches, belly pain and extreme fatigue.  On unspecified date, the patient had an ultrasound, a complete blood cell count (CBC), a serum C-reactive protein test (CRP), and an Epstein-Barr virus antibodies screen; however, no results were reported.  The patient sought unspecified medical attention by being seen in the office.  At the time of this report, the patient's body aches and belly pain and extreme fatigue have persisted.  No additional information was provided.  Additional information has been requested. This is in follow-up to report(s) previously submitted on 4/14/2008.  Follow-up information received 25-MAR-2008 from the licensed practical nurse, reported that the patient had modest splenomegaly with abdominal pain, sweats, no fever, no pruritis noted approximately 4 weeks after receiving the first dose of GARDASIL.  Patient "worked up for possible mono, EAV (-)".  On 10-MAR-2008, the patient had an ultrasound that showed enlarged spleen (previously reported as medical history).  On 17-MAR-2008, the patient was seen and still had abdominal pain.  Follow-up information received 07-APR-2008 from the nurse practitioner reported "Patient was back to normal." Office thinks might have been viral syndrome." "Labs and CBC followed" (no results reported).  Additional information has been requested.
A dose of Moderna bivalent of 0.25 ml was administered, when it should have been 0.5 ml..
This spontaneous report as received from a registered nurse refers to an unknown number of patients of unknown age. The nurse reported that an unknown number of patient may have received (Merck) VARIVAX injection (lot#, dose and route were not reported) stored on multiple occasions at higher than recommended temperatures. No adverse effect reported. No additional information reported. Additional information has been requested. Incorrect product storage.
wet cough; This is a spontaneous report from contactable consumer Pfizer-sponsored program. A contactable consumer reported for an 88-year-old male patient (her father).  An 88-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: UNKNOWN), dose 1 via an unspecified route of administration on 20Feb2021 (at the age 88-years-old) as dose 1, single for covid-19 immunisation. Medical history included cough from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. Before the first dose patient already had a cough but for reporter it appeared that after the first dose the cough seems more like wet cough. Reporter was asking if that was something they need to be concerned about or does her father need to consult the HCP. Patient tested negative for the COVID-19 test. The patient underwent lab tests and procedures which included sars-cov-2 test negative. The outcome of event was unknown.  No follow-up attempts are possible, information about lot/batch number cannot be obtained.
No adverse reaction was reported to local health department by client and/or family. Health Department received death report that client died of natural causes on 11/8/2022 at 1655.  No autopsy was performed per death report and client has history of tobacco use, COPD, and Hypertensive and Atherosclerotic Cardiovascular Disease. Due to client receiving bivalent booster on 11/04/2022 VAERS is being completed.
Already had both shots, got another one yesterday; This case was reported by a consumer via interactive digital media and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st and 2nd dose on an unknown date few years back).   On 26th September 2022, the patient received the 3rd dose of Shingrix. On 26th September 2022, unknown after receiving Shingrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 27-SEP-2022 Reporter's Comment: This case was reported by a patient via interactive digital media. The patient forgot that he/she had already had both Shingrix shots a few years back and got another one yesterday (from the date of reporting) and asked would this have an adverse effect. Additional supportive information: As patient already had both the dose of Shingrix few years back and had 3rd dose of Shingrix vaccine again, which led to extra dose administered.
pain; weakness; Heavy period/Short in between time/interval between periods shortened; periods are very heavy; This is a spontaneous report from a contactable consumer (patient). A 35-years-old female received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: ER8735), dose 1 via an unspecified route of administration on shoulder on 16Apr2021 16:30 (at the age of 35-years-old) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On 04May2021, the patient reported that since first covid vaccine my periods were very heavy with at least 2x200 Ibuprofen 3 times a day. Pain lasts for at least 2 full days (It used to be 1 say. Ibuprofen/heavy periods). Weakness. Interval between periods shortened. Patient reported heavy period/short in between on 31May2021 and 27Jun2021. Patient received treatment of 2x200 Ibuprofen 3 times a day for the events. The clinical outcome was recovering for event heavy bleeding and outcome was unknown for the other events.   Follow-up attempts are completed. No further information is expected.
Patient is fully vaccinated. Patient presents to the ED after testing positive for COVID - 19 on 1/3/2022.  Complaining of cough, nausea or vomiting, diarrhea. Patient also complaining of generalized myalgias.Associated symptoms: congestion, cough, diarrhea, fatigue, fever, headaches, myalgias, nausea, rhinorrhea, shortness of breath and vomiting. BP 121/52  | Pulse 90  | Temp 99 °F (37.2 °C) (Oral)  | Resp 18  | Ht 160 cm (5' 3")  | Wt 74.8 kg (165 lb)  | LMP 12/21/2021  | SpO2 100%  | BMI 29.23 kg/m²   CXR normal.  Treatment:  toradol, decadron, robaxin, tylenol, robitussin. discharged home.
Patient presented to obstetric care unit at 36+ weeks of pregnancy complaining of abdominal pain.  Ruled by provider to be unlikely due to pregnancy or gallbladder but no definative diagnosis made.  Comprehensive labs were drawn.  Lab returned showing PLT count of 152 (prior lab 8/31/09 - 210).  Patient was held for 24 hour observation and a few days later held for observation again due to decreased plts and proteinuria.  She was admitted for induction of labor the following day.  Platelets continued to decrease during that time until 11/3 when levels began to resolve. Patient was discharged without further follow-up for thrombocytopenia. 11/17/09 Hospital records received from date 10/26/09. DX: Abdominal pain. Pt c/o abdominal pain, 36 weeks pregnant. Assessment: WNL, FHR(+)
Erythema and edema of about 4cm by 2cm on lateral aspect of R arm - not tender.